<?xml version="1.0"?>
<Articles JournalTitle="Basic &amp; Clinical Cancer Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Basic &amp; Clinical Cancer Research</JournalTitle>
      <Issn>2228-6527</Issn>
      <Volume>13</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>01</Month>
        <Day>04</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability</title>
    <FirstPage>55</FirstPage>
    <LastPage>62</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Aycicek</LastName>
        <affiliation locale="en_US">Pediatric Hematology Oncology</affiliation>
      </Author>
      <Author>
        <FirstName>Tuba Nur</FirstName>
        <LastName>Tahtakesen</LastName>
        <affiliation locale="en_US">Basaksehir Cam and Sakura City Hospital Pediadric Hematology/Oncolog Clinic 34480, Istanbul, TURKEY.</affiliation>
      </Author>
      <Author>
        <FirstName>Cengiz</FirstName>
        <LastName>Bayram</LastName>
        <affiliation locale="en_US">Basaksehir Cam and Sakura City Hospital Pediadric Hematology/Oncolog Clinic 34480, Istanbul, TURKEY.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>03</Month>
        <Day>07</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Aim: To investigate invitro ursodeoxy cholic acid (UDCA) and N-acetyl cystein (NAC) effect on blast cell viability in children newly diagnosed with acute lymphoblastic leukemia (ALL).
&#xD;

Patients and Methods: Samples were obtained from a total of 52 newly diagnosed ALL patients aged 1 to 17 years. UDCA and NAC were added at clinical relevant concentrations (0-300 micrograms) onto 5x10^5 cells were treated at room temperature in dark place. Untreated and treated cells were stained with 7AAD PE and analyzed by flow cytometry.
&#xD;

Results: Median (IQR) blast percentage and incubation time were 90% (11) and 18 (1.5) hours, respectively.&#xA0; Dead/live blast cells ratio (7AAD+) was lower in lymphoblasts treated with all NAC concentration than untreated controls (p &lt; 0.001). The use of NAC was noted to,&#xA0; regardless of concentration, contributed to lymphoblasts viability. On the contrary, dead/live blast cells ratio in samples treated with UDCA at the above-mentioned concentrations was relatively high, suggesting the protection role for both hepatotoxicty and against leukemia. However, the difference was not statistically significant (P &gt;0.05). There was also no correlation between different doses of&#xA0; UCDA and NAC&#xA0; regarding blast cell viability (P &gt; 0.232).
&#xD;

Conclusion: The present study showed that in vitro&#xA0; NAC use had a protective effect on lymphoblast viability in newly diagnosed ALL patients before start of chemotherapy, and also patient-derived ALL cells can be successfully analyzed ex vivo in a short&#xA0; and different period of time without loss of blasts.</abstract>
    <web_url>https://bccr.tums.ac.ir/index.php/bccrj/article/view/379</web_url>
    <pdf_url>https://bccr.tums.ac.ir/index.php/bccrj/article/download/379/476</pdf_url>
  </Article>
</Articles>
